Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Mueang, Phitsanulok 65000, Thailand.
Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Mueang, Phitsanulok 65000, Thailand.
J Integr Med. 2022 Mar;20(2):114-125. doi: 10.1016/j.joim.2022.01.008. Epub 2022 Jan 31.
Propolis and honey have been studied as alternative treatments for patients with coronavirus disease 2019 (COVID-19). However, no study has yet summarized the full body of evidence for the use of propolis and honey in COVID-19 prevention and treatment.
This study systematically reviews the mechanisms of propolis and honey against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and current evidence for the use of propolis and honey in COVID-19 prevention and treatment.
A systematic search was conducted of electronic databases including PubMed, Scopus, ScienceDirect, and Cochrane Library from their inceptions to April 2021.
Studies that evaluated the effect of propolis or bee products against SARS-CoV-2 using in silico methods, clinical studies, case reports and case series were included.
A standardized data extraction form was used, and data were extracted by two independent reviewers. Narrative synthesis was used to summarize study results concerning the use of propolis or honey in COVID-19 prevention and treatment and their potential mechanisms of action against SARS-CoV-2.
A total of 15 studies were included. Nine studies were in silico studies, two studies were case reports, one study was a case series, and three studies were randomized controlled trials (RCTs). In silico studies, using molecular docking methods, showed that compounds in propolis could interact with several target proteins of SARS-CoV-2, including angiotensin-converting enzyme 2, the main protease enzyme, RNA-dependent RNA polymerase, and spike protein. Propolis may have a positive effect for clinical improvement in mild and moderate-to-severe COVID-19 patients, according to case reports and case series. The included RCTs indicated that propolis or honey could probably improve clinical symptoms and decrease viral clearance time when they were used as adjuvant therapy to standard of care.
In silico studies showed that compounds from propolis could interact with target proteins of SARS-CoV-2, interfering with viral entry and viral RNA replication, while clinical studies revealed that propolis and honey could probably improve clinical COVID-19 symptoms and decrease viral clearance time. However, clinical evidence is limited by the small number of studies and small sample sizes. Future clinical studies are warranted.
蜂胶和蜂蜜已被研究为治疗 2019 年冠状病毒病(COVID-19)患者的替代疗法。然而,尚无研究总结蜂胶和蜂蜜在 COVID-19 预防和治疗中的全部证据。
本研究系统综述了蜂胶和蜂蜜对抗严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的作用机制,以及蜂胶和蜂蜜在 COVID-19 预防和治疗中的应用的现有证据。
系统检索了包括 PubMed、Scopus、ScienceDirect 和 Cochrane Library 在内的电子数据库,检索时间从数据库建立到 2021 年 4 月。
纳入使用计算机模拟方法、临床研究、病例报告和病例系列研究评估蜂胶或蜂产品对 SARS-CoV-2 作用的研究。
使用标准化数据提取表,由两名独立的审查员提取数据。使用叙述性综合方法总结关于蜂胶或蜂蜜在 COVID-19 预防和治疗中的应用及其对 SARS-CoV-2 的潜在作用机制的研究结果。
共纳入 15 项研究。9 项为计算机模拟研究,2 项为病例报告,1 项为病例系列,3 项为随机对照试验(RCT)。计算机模拟研究使用分子对接方法表明,蜂胶中的化合物可与 SARS-CoV-2 的几个靶标蛋白相互作用,包括血管紧张素转换酶 2、主要蛋白酶、RNA 依赖性 RNA 聚合酶和刺突蛋白。病例报告和病例系列研究表明,蜂胶可能对轻度和中重度 COVID-19 患者的临床改善有积极作用。纳入的 RCT 表明,蜂胶或蜂蜜作为标准治疗的辅助治疗可能改善临床症状并缩短病毒清除时间。
计算机模拟研究表明,蜂胶中的化合物可与 SARS-CoV-2 的靶标蛋白相互作用,干扰病毒进入和病毒 RNA 复制,而临床研究表明,蜂胶和蜂蜜可能改善 COVID-19 患者的临床症状并缩短病毒清除时间。然而,由于研究数量少、样本量小,临床证据有限。需要进一步的临床研究。